cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Mustofa
Contact Email
mustofafk@ugm.ac.id
Phone
+6281328749273
Journal Mail Official
mustofafk@ugm.ac.id
Editorial Address
Department of Pharmacology and Therapy Radioputro Building 2nd Floor Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada Jl. Farmako Sekip Utara, Yogyakarta 55281 Indonesia
Location
Kab. sleman,
Daerah istimewa yogyakarta
INDONESIA
Indonesian Journal of Pharmacology and Therapy
Published by Universitas Gadjah Mada
ISSN : -     EISSN : 2745455X     DOI : https://doi.org/10.22146/ijpther.10147
Core Subject : Health, Science,
Immunology & microbiology Medicine & Pharmacology
Indonesian Journal of Pharmacology and Therapy (IJPTher ) is a scientific journal which published by Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI). IJPTher is an open-access, and double-blind peer-reviewed journal published three Issues a year. IJPTher aims to communicate high-quality articles in the fields of pharmacology. IJPTher publishes original articles, review articles, case reports and book reviews in the fields of pharmacology including basic pharmacology, clinical pharmacology, pharmacotherapy, pharmacoepidemiology, pharmacogenetics, pharmacogenomics, pharmacoeconomic, toxicology and toxicogenomics.
Arjuna Subject : Pharmacology, Toxicology and Pharmaceutics - Pharmacology, Toxicology and Pharmaceutics (Lain-Lain)
Articles 10 Documents
 1 
Search results for , issue "Vol 2 No 3 (2021)" : 10 Documents clear
The effect of red cabbage extract to serum MDA levels in rats after maximum physical activity Haris, Nadia Husna; Nugroho, Trilaksana; Utomo, Astika Widy; Yora Nindita
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.1117

Abstract

The maximum physical activity led to generate of free radical levels in the human body called oxidative stress. Red cabbage is well known as the vegetable containing highest anthocyanin among various other head cabbage plants. Anthocyanin is an antioxidant which is proven can prevent oxidative stress through reduction of MDA levels. The study aimed to investigate the effect of red cabbage extract (RCE) on MDA levels in rat after doing maximum physical activity. It was a true experimental study with post-test only control group design. Twenty-four male albino Wistar rats were used in this study. The rats were randomly divided into four groups i.e. the rats receiving maximum physical activity without and with RCE administration at dose of 86 mg/kg BW for eight days and the rats not receiving maximum physical activity without and with RCE administration. A swim test was used for maximum physical activity intervention. Serum MDA levels were measured using TBARS method. Data were analysed using one-way Anova followed by post-hoc LSD. A p value <0.005 was considered to be significant. The results showed that the rats treated with RCE both receiving maximum physical activity or not showed significant MDA reduction compared to rats without treated RCE (p=0.011 and p=0.027, respectively). Meanwhile, there was no significant difference in serum MDA levels between rats treated with RCE receiving maximum physical activity and rats not treated with RCE and not receiving maximum physical activity (p=0.540). Supplementation of RCE can reduce serum MDA levels in rats with and without maximum physical activity. Further study to investigate effective dose of RCE is recommended.
Potential neurological applications of Centella asiatica: a brief review Gofir, Abdul; Wibowo, Samekto; Hakimi, Mohammad
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.1693

Abstract

Centella asiatica (C. asiatica) or gotu kola has been used traditionally in many Asian countries as herbal medicines for many conditions, such as headache, asthma and memory enhancement. Centella asiatica has been also widely investigated for its neuroprotective effects in animal disease model including epilepsy, Alzheimer’s and Parkinson’s diseases. A brief review of neurological effects studies of C. asiatica in animal model was reported. Eligible studies published through December 2020 from PubMed and EMBASE journal data base were collected. Any keywords related to C. asiatica or gota kola AND neurological conditions were used. The results showed that several experimental studies concerning the neuroprotective properties of C. asiatica have been reported. Phytochemical studies reported that C. asiatica contained many bioactive compounds in which triterpenoids are the most identified. Furthermore, the triterpenoids have proven to have neuroprotective effect due to their effects of anti-inflammatory, antioxidant, improvement of mitochondrial dysfunctions, and increased brain-derived neurotrophic factors. Further studies are needed to investigate the neuroprotective mechanisms of C. asiatica. In conclusion, C. asiatica might have potential as an alternative medicine for neurological conditions, such as stroke, epilepsy, Alzheimer’s and Parkinson’s disease.
The potential of polyphenols from natural ingredients against SARS-CoV-2 infection: A review Hendrayana, Made Agus; I Made Jawi; Dewa Made Sukrama; Dewa Ngurah Suprapta
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2310

Abstract

All countries in the world are facing the coronavirus disease-19 (COVID-19) pandemic which has resulted in various crises. To date, there is no effective treatment in controlling COVID-19. Many clinical trials of approved drugs against COVID-19 were conducted. However, the results were inconclusive, even severe adverse effects were reported. The new effective drugs are therefore urgently needed. Herbal medicines have been widely used by community to enhance the body immune system during COVID-19 pandemic. Polyphenols are large group of active compounds found in the natural ingredients. These compounds have been proven to have biological activity against various pathogen infections including viral infection. During COVID-19 pandemic, various polyphenol compounds from various medicinal plants have been investigated for their activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) both in silico and in vitro. Among the polyphenols investigated, some of them namely papyriflavonol, catechin gallate, gallocatechin gallate, luteolin, quercetin, tangeretin, naringenin, herbacetin, emodin, eriodyctiol, fenoterol, baicalin, myricetin, quercetagetin exhibited strong activity against SARS-CoV-2. The possibilities of mechanism of actions as antiSARS-CoV-2 of these polyphenols were 1) bind to the N protein causing the inhibition of viral transcription and replication; 2) inhibit the binding of S protein to ACE2 receptors preventing the entry of the virus into the host cells; 3) inhibit 3CLpro function inhibiting the viral transcription and maturation; and 4) bind directly to the ACE2 receptor. In conclusion, some polyphenol compounds from nature ingredients are potential to develop to be future antiSARS-CoV-2. However, further the pre-clinical and clinical studies are required to strengthen existing evidence.
Application of solid lipid nanoparticles preparation in infection caused by antibiotic-resistant bacteria Prastiwi, Nenes; Ervina; Lesbatta, Kezia
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2318

Abstract

Solid lipid nanoparticles (SLN) is a potential alternative method for drug delivery due to its good stability, low toxicity, can be modified and controlled in drug release, as well as can be produced on a large scale. The SLNs are composed of solid lipids stabilized by emulsifiers. The lipids used for SLN are physiological lipids that easily tolerated by the body. These characteristics make SLN as a potential delivery system that can increase the efficiency of an antibiotics preparation. The development of bacterial resistance to antibacterial has become serious health problems in infectious diseases. Solid lipid nanoparticles is a compelling choice as a drug delivery system that can reduce the problem of the bacterial resistance. This review discussed the role of SLN as a drug carrier system which includes the characteristics and structure of SLN, its pharmacokinetic properties, bacterial resistance mechanism, and SLN mechanism in reducing bacterial resistance.
Potential of orchid as antifungal agent resources: a scoping review Furqi Sholekhatun Sityardi; Sufi Desrini
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2325

Abstract

In 2017, one billion people contracted fungal infection with 11.5 million people contracted life-threatening infection and 1.5 million death per year. Orchid is a plant that grows in tropical and sub-tropical countries, the same places where fungal infection occurrence is high. On previous studies reported that orchid contains alkaloids and polyphenols such as flavonoid, and phenol acid. The review aimed to identify the orchid as a potential antifungal resource. A scoping review was used. The type of articles reviewed were original articles obtained from five electronic journal databases published within 2012-2021. Three articles reported similar result which was that orchid extract has a significant antifungal activity although the part of plant used was different, ranging from the root, to the leaf. Two articles reported a specific antifungal activity against Candida albicans while the remaining one against Trichophyton rubrum. In conclusion, the root, leaf, branch, and flower extracts of orchid is potential antifungal resources.
The potential effect of natural compounds from Indonesian spices in alleviating inflammation due to the coronavirus disease (COVID-19): a narrative review Yuliana, .
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2366

Abstract

COVID-19 causes increasing of inflammatory cytokines even cytokine storm in the severe condition. Enhance body immune system is one strategy against COVID-19. Spices in traditional Indonesian cuisine are believed as boost immunity. They contain active compounds such as curcumin, allicin, quercetin and capsaicin which can be used to alleviate inflammation. In this literature review, the potency of curcumin, allicin, quercetin, and capsaicin in alleviating inflammation due the COVID-19 was reported. Literatures were gathered from PubMed, Science Direct, and Google Scholar search engines. COVID-19 causes the increase of proinflammatory cytokine levels such as TNFα and IL-6. Curcumin, allicin, quercetin, and capsaicin regulate the expression of proinflammatory cytokines. These nutritional agonists of peroxisome proliferator-activated receptor-γ (PPAR-γ) showed inhibitory effects on pro-inflammatory cytokines and promote immune cell differentiation into anti-inflammatory phenotypes. Curcumin has an anti-inflammatory effect that can prevent pneumocytes, renal cells, and cardiomyocytes damages. Allicin and quercetin can decrease TNFα and IL-6 levels due to they can increase the superoxide dismutase (SOD) levels. In conclusion, curcumin, allicin, quercetin and capsaicin can enhance body immune system due to their anti-inflammatory effect through down-regulation of the inflammatory cytokines expression. These spices could be used as adjuvant therapy to boost body immune system against COVID-19.
The comparison of colchicine and standard treatment in COVID-19 patients: A mini review Kwok, Yasmeen; Dwi Aris Agung Nugrahaningsih; Woro Rukmi Pratiwi
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2381

Abstract

Coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020. There are several drugs used at different stages of the disease, but none seem to be completely effective. In the absence of any known therapy, many drugs have been tested, including colchicine. Colchicine differs from these other therapies in having pleiotropic mechanism of action, being less potent on any single target, and being an oral agent. It is also a better option since colchicine is not immunosuppressive, is not known to increase risk of infection, and is inexpensive. The aim of this study was to provide evidence of the role of colchicine in improving clinical outcome and reducing death rate of COVID-19 patients through literature mini-review. A mini-review, composed of previous RCTs comparing the use of colchicine in COVID-19 with standard care or placebo under the keyword “COVID-19”, “COVID”, “coronavirus”, “SARS-CoV-2”, “coronavirus disease”, “Colchicine”, “CAS 64-86-8”, “standard treatment”, “standard care”, “standard of care”, “common treatment”, “placebo”, “clinical improvement”, and “clinical response”. The addition of colchicine to standard treatment can be beneficial in treating COVID-19. Studies included showed that colchicine has significantly improved time to clinical deterioration compared to the control group. Colchicine reduced the length of hospitalization and the need for supplemental oxygen therapy. One of the included studies mentioned that in outpatient settings, colchicine can prevent hospitalization and even death. Colchicine can improve the clinical outcome on CRP levels, the number of patients that need mechanical ventilation, and death rate in COVID-19 patients. The addition of colchicine to standard treatment should be considered to prevent clinical deterioration and death. Colchicine reduces the number of adverse effects in COVID-19 patients except for gastrointestinal adverse effects, especially diarrhea, which is consistently more common in the colchicine groups.
Molecular docking study of Indonesian phytochemicals as inhibitor of 6-HB formation by binding to HR1 subunit of SARSCOV-2 S2 protein Julianus, Jeffry; Phebe Hendra; Maywan Hariono; Nico Frederick; Satrio Ardyantoro; Mustofa; Jumina
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2392

Abstract

Coronavirus disease 2019 (COVID-19) is still as global pandemic. No officially drugs to treat COVID-19 are available until now. Increasing number of patients and deaths trigger new antiCOVID-19 discovery efforts. In this study, we have conducted in silico screening employing molecular docking for Indonesian phytochemicals. Docking process was performed by employing AutoDock4 software on crystal structure 6VSB. Based on molecular docking results, several compounds had potential as antiCOVID-19 drugs, such as β-carotene, veramiline, ecliptalbine, betulinic acid, and lupeol. β-carotene was the most potential compound to treat COVID-19.
Clinical trial and therapeutical progress of COVID-19 treated with remdesivir: A review Anna Maria Manullang; Monia Agni Wiyatami; Mahulauw, Muhammad Azril Hardiman
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2625

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that first reported in Wuhan City, China. Most confirmed cases of COVID-19 develop mild, moderate, severe to critical symptoms. One of the therapies given and of concern is remdesivir. Remdesivir is an antiviral with a broad spectrum that has activity against various types of viruses including Middle East respiratory syndrome coronavirus (MERS-CoV) and SARS-CoV. The aim of this review was to evaluate the clinical trial and the therapeutical progress of remdesivir in the treatment of COVID-19 patients. Databases used for this review were Google Scholar, JAMA, PubMed and Science Direct library. The inclusion criteria were covering any literature using remdesivir in clinical studies and COVID-19 therapy published from December 2019 to October 2020. Overall no pattern of laboratory abnormalities and clinically significant changes in vital signs or ECG shifts was observed in patients receiving remdesivir. The decision to use remdesivir in COVID-19 treatment should consider its potential benefits and risks.
Current pharmacological treatments for COVID-19: A narrative review Sudi Indra Jaya; Yacobus Christian Prasetyo
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2881

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has lasted more than one year. The number of daily cases and the number of deaths is still changing dynamically. As of this writing, specific drugs for COVID-19 are not yet available. This review aims to describe the key clinical evidence in pharmacological treatments for COVID-19. The article search process was carried out on the PubMed database with a combination of keywords ((“COVID-19”) OR (“SARS-CoV-2”)) AND ((“treatment”) OR (“therapy”)). In this article, there were six drugs reviewed that is corticosteroids, remdesivir, lopinavir-ritonavir, hydroxychloroquine, ivermectin, and interleukin-6 (IL-6) receptor blockers. Hydroxychloroquine, lopinavir-ritonavir, remdesivir, and ivermectin were not recommended for COVID-19 treatments regardless of disease severity and duration of symptoms. Therefore, they were excluded from the list of drugs for the treatment of COVID-19 by World Health Organization (WHO) stated strong recommendations in favor of two drugs, namely systemic corticosteroids and IL-6 receptor blockers namely tocilizumab or sarilumab. Both of them are recommended for the treatment of patients with severe and critical covid-19 so they are included in the list of COVID-19 therapeutic drugs by WHO.

Page 1 of 1 | Total Record : 10

 1 

Filter by Year

2021 2021


Reset
Filter By Issues
All Issue Vol 6 No 3 (2025) Vol 6 No 2 (2025) Vol 6 No 1 (2025) Vol 5 No 3 (2024) Vol 5 No 2 (2024) Vol 5 No 1 (2024) Vol 4 No 3 (2023) Vol 4 No 2 (2023) Vol 4 No 1 (2023) Vol 3 No 3 (2022) Vol 3 No 2 (2022) Vol 3 No 1 (2022) Vol 2 No 3 (2021): Special Issue: COVID-19 Vol 2 No 3 (2021) Vol 2 No 2 (2021) Vol 2 No 1 (2021) Vol 1 No 2 (2020) Vol 1 No 1 (2020) More Issue